Literature DB >> 15706135

Performance of male C57BL/6J mice and Wistar rats in the water maze following various schedules of phencyclidine treatment.

J Podhorna1, M Didriksen.   

Abstract

In order to establish an animal model of cognitive impairments relevant to schizophrenia, we set out to obtain an optimal treatment protocol with phencyclidine (PCP) that would lead to robust cognitive impairment with minimal PCP-related adverse effects. Effects of various doses (0.63-5 mg/kg), pre-treatment period (0, 3, 7 and 10 days before the beginning of acquisition) and treatment schedules (before the first or immediately after the last trial on each day) of PCP on the performance of male C57BL/6J mice and Wistar rats in the spatial version of the water maze were studied. In mice, a 10-day pre-treatment period was required to prevent PCP-induced motor impairments, whereas a 3-day pre-treatment was sufficient in rats. PCP impaired spatial learning in both rats and mice, if animals were administered PCP prior to the first trial. The optimal dose was 2.5 mg/kg. In contrast, animals given PCP immediately after the daily training sessions performed as well as controls. Thus, PCP impairs spatial learning in the water maze only when present in the organism. It can be concluded that PCP interferes with learning, and perhaps retrieval, but not consolidation of newly acquired information.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15706135     DOI: 10.1097/00008877-200502000-00003

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  12 in total

1.  Effects of metabotropic glutamate receptor 2/3 agonism and antagonism on schizophrenia-like cognitive deficits induced by phencyclidine in rats.

Authors:  Nurith Amitai; Athina Markou
Journal:  Eur J Pharmacol       Date:  2010-04-02       Impact factor: 4.432

Review 2.  Disruption of performance in the five-choice serial reaction time task induced by administration of N-methyl-D-aspartate receptor antagonists: relevance to cognitive dysfunction in schizophrenia.

Authors:  Nurith Amitai; Athina Markou
Journal:  Biol Psychiatry       Date:  2010-05-21       Impact factor: 13.382

3.  Repeated phencyclidine administration alters glutamate release and decreases GABA markers in the prefrontal cortex of rats.

Authors:  Nurith Amitai; Ronald Kuczenski; M Margarita Behrens; Athina Markou
Journal:  Neuropharmacology       Date:  2011-01-14       Impact factor: 5.250

Review 4.  The subchronic phencyclidine rat model: relevance for the assessment of novel therapeutics for cognitive impairment associated with schizophrenia.

Authors:  Sanna K Janhunen; Heta Svärd; John Talpos; Gaurav Kumar; Thomas Steckler; Niels Plath; Linda Lerdrup; Trine Ruby; Marie Haman; Roger Wyler; Theresa M Ballard
Journal:  Psychopharmacology (Berl)       Date:  2015-06-14       Impact factor: 4.530

5.  Genetic background differences and nonassociative effects in mouse trace fear conditioning.

Authors:  Dani R Smith; Michela Gallagher; Mark E Stanton
Journal:  Learn Mem       Date:  2007-09-05       Impact factor: 2.460

Review 6.  Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia.

Authors:  Jared W Young; Susan B Powell; Victoria Risbrough; Hugh M Marston; Mark A Geyer
Journal:  Pharmacol Ther       Date:  2009-03-06       Impact factor: 12.310

7.  Antagonism of phencyclidine-induced stimulus control in the rat by other psychoactive drugs.

Authors:  J C Winter
Journal:  Pharmacol Biochem Behav       Date:  2007-08-15       Impact factor: 3.533

8.  Reversal of PCP-induced learning and memory deficits in the Morris' water maze by sertindole and other antipsychotics.

Authors:  Michael Didriksen; Torben Skarsfeldt; Jørn Arnt
Journal:  Psychopharmacology (Berl)       Date:  2007-04-04       Impact factor: 4.415

9.  Cognitive-disruptive effects of the psychotomimetic phencyclidine and attenuation by atypical antipsychotic medications in rats.

Authors:  Nurith Amitai; Svetlana Semenova; Athina Markou
Journal:  Psychopharmacology (Berl)       Date:  2007-05-12       Impact factor: 4.415

10.  Assessing the Cognitive Translational Potential of a Mouse Model of the 22q11.2 Microdeletion Syndrome.

Authors:  Simon Ro Nilsson; Kim Fejgin; Francois Gastambide; Miriam A Vogt; Brianne A Kent; Vibeke Nielsen; Jacob Nielsen; Peter Gass; Trevor W Robbins; Lisa M Saksida; Tine B Stensbøl; Mark D Tricklebank; Michael Didriksen; Timothy J Bussey
Journal:  Cereb Cortex       Date:  2016-08-09       Impact factor: 5.357

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.